注射用重组改构人肿瘤坏死因子治疗恶性胸腔积液临床观察

目的：探讨注射用重组改构人肿瘤坏死因子（recombinant metant human tumor necrossis factor,rmhT-NF）和顺铂（cisplatin,DDP）治疗恶性胸水的疗效和不良反应。方法：将60例恶性胸水患者随机分为rmhTNF组和DDP组,观察各组的疗效、起效时间和副反应。结果：TNF组总有效率86.7%,DDP组总有效率66.7%,TNF组效果好于DDP组,P〈0.05,有统计学意义。结论：使用rmhTNF治疗恶性胸水起效较快,疗效确切,较顺铂治疗副反应小,操作简便,有临床应用价值。

A clinical observation of malignant pleural effusion treated by intrapleural perfusion with recombinant mutant human tumor necrosis factor

Objective：To approach the clinical effect and adverse reaction of recombinant metant human tumor necrossis factor（rmhTNF） and DDP in the treatment of malignant pleural effusion.Methods： Sixty patients with maligant pleural effusion were randomly devided into two groups：groupTNF was infused with rmhTNF,the another one was infused with DDP.The effective rate,responding time and adverse reaction were observed.Results： The total effective rate of rmhTNF group was 86.7%,while it was 66.7% in groupDDP.There was a significant difference between two groups（P0.05）.Conclusion： The rmhTNF is more effective and responds qulickly with less adverse reaction for treatment of maliganat pleural effusion.